Overactive Bladder - Pipeline Review, H1 2017

Publisher Name :
Date: 09-May-2017
No. of pages: 114
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H1 2017, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 7, 5, 5, 2, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).

  • The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Overactive Bladder - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Overactive Bladder - Overview
Overactive Bladder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Overactive Bladder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Overactive Bladder - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Allergan Plc
Asahi Kasei Pharma Corp
Astellas Pharma Inc
Dompe Farmaceutici SpA
Dong-A ST Co., Ltd.
FemmePharma Global Healthcare Inc
Hanmi Pharmaceuticals Co Ltd
Hydra Biosciences Inc
Ion Channel Innovations LLC
Ipsen SA
Jeil Pharmaceutical Co Ltd
Juniper Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Lipella Pharmaceuticals Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
Ono Pharmaceutical Co Ltd
Recordati SpA
Roivant Sciences Ltd
Sanofi
Seoul Pharma Co Ltd
Taris Biomedical LLC
TheraVida Inc
Toray Industries Inc
XuanZhu Pharma Co Ltd
Overactive Bladder - Drug Profiles
(mirabegron + solifenacin succinate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(solifenacin succinate + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abobotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-71441 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AK-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-8010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DFL-23448 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fadanafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HC-067047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIP-1503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPR-2579 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirabegron ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-8577 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Antagonize PACAP Receptor for Pelvic Pain Syndrome and Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pVAX-hSlo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-0438 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RVT-901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-244181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize PTGER1 for Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solabegron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solabegron hydrochloride MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solifenacin succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solifenacin succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPO-1406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THVD-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trospium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vibegron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Overactive Bladder - Dormant Projects
Overactive Bladder - Discontinued Products
Overactive Bladder - Product Development Milestones
Featured News & Press Releases
Oct 27, 2016: Velicept Therapeutics Names Clarence Young, M.D., Chief Medical Officer
Oct 07, 2016: Astellas Filed Lawsuit against Patent Infringement of Myrbetriq in the United States
Oct 05, 2016: Velicept Therapeutics Announces FDA Acceptance of IND Application of Novel, Once-Daily Formulation of Solabegron for the Treatment of Overactive Bladder
Sep 27, 2016: Allergan to Present New Data at the American Urogynecologic Society Annual Meeting in Denver
May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego
Mar 21, 2016: Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women
Jan 11, 2016: Juniper Pharmaceuticals Submits Pre-IND Meeting Request for its First Intra-vaginal Ring Product
Oct 15, 2015: Allergan Announces New Long-Term OnabotulinumtoxinA Treatment Study Results at the American Urogynecologic Society Meeting
Jun 15, 2015: NeXeption Forms New Company Velicept Therapeutics Intends to Merge with AltheRx Pharmaceuticals to Advance Solabegron for the Treatment of Overactive Bladder
May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
May 05, 2015: Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting
Dec 08, 2014: Lipella's Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial
Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder
Oct 17, 2013: AltheRx Pharmaceuticals is Granted U.S. Patent for Use of Solabegron in Combination with Antimuscarinics for the Treatment of Overactive Bladder
Sep 11, 2013: Allergan's BOTOX Receives Authorisation for the Treatment of Overactive Bladder in the UK
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Overactive Bladder, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Overactive Bladder - Pipeline by Addex Therapeutics Ltd, H1 2017
Overactive Bladder - Pipeline by Allergan Plc, H1 2017
Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp, H1 2017
Overactive Bladder - Pipeline by Astellas Pharma Inc, H1 2017
Overactive Bladder - Pipeline by Dompe Farmaceutici SpA, H1 2017
Overactive Bladder - Pipeline by Dong-A ST Co., Ltd., H1 2017
Overactive Bladder - Pipeline by FemmePharma Global Healthcare Inc, H1 2017
Overactive Bladder - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Overactive Bladder - Pipeline by Hydra Biosciences Inc, H1 2017
Overactive Bladder - Pipeline by Ion Channel Innovations LLC, H1 2017
Overactive Bladder - Pipeline by Ipsen SA, H1 2017
Overactive Bladder - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
Overactive Bladder - Pipeline by Juniper Pharmaceuticals Inc, H1 2017
Overactive Bladder - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
Overactive Bladder - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Overactive Bladder - Pipeline by Lipella Pharmaceuticals Inc, H1 2017
Overactive Bladder - Pipeline by Merck & Co Inc, H1 2017
Overactive Bladder - Pipeline by Mezzion Pharma Co Ltd, H1 2017
Overactive Bladder - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Overactive Bladder - Pipeline by Recordati SpA, H1 2017
Overactive Bladder - Pipeline by Roivant Sciences Ltd, H1 2017
Overactive Bladder - Pipeline by Sanofi, H1 2017
Overactive Bladder - Pipeline by Seoul Pharma Co Ltd, H1 2017
Overactive Bladder - Pipeline by Taris Biomedical LLC, H1 2017
Overactive Bladder - Pipeline by TheraVida Inc, H1 2017
Overactive Bladder - Pipeline by Toray Industries Inc, H1 2017
Overactive Bladder - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
Overactive Bladder - Dormant Projects, H1 2017
Overactive Bladder - Dormant Projects, H1 2017 (Contd..1), H1 2017
Overactive Bladder - Dormant Projects, H1 2017 (Contd..2), H1 2017
Overactive Bladder - Dormant Projects, H1 2017 (Contd..3), H1 2017
Overactive Bladder - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Overactive Bladder, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting&hellip
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and&hellip
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries,&hellip
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the&hellip
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The&hellip
  • Urinary Incontinence - Pipeline Review, H2 2017
    Published: 11-Jul-2017        Price: US 2000 Onwards        Pages: 69
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H2 2017, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder's contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors includ......
  • Interstitial Cystitis - Epidemiology Insights to 2025
    Published: 05-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight " Interstitial Cystitis - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Interstitial Cystitis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Interstitial Cystitis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need assoc......
  • Urinary Incontinence - Epidemiology Insights to 2025
    Published: 05-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight " Urinary Incontinence - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Urinary Incontinence in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Urinary Incontinence prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associat......
  • Bladder Pain - Pipeline Insight, 2017
    Published: 05-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, " Bladder Pain -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Bladder Pain. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Bladder Pain. This report provides information on the therapeutic development for Bladder Pain, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well as disco......
  • Cystitis - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 05-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Cystitis - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Cystitis for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Cystitis forecasted market share for ten years to 2025 segmented by seven major markets. In addition, the report includes the historical and forecasted epidemiologica......
  • Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 05-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Interstitial Cystitis for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Interstitial Cystitis forecasted market share for ten years to 2025 segmented by seven major markets. In addition, the report includes the h......
  • Urinary Incontinence - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 05-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Urinary Incontinence - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Urinary Incontinence for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Urinary Incontinence forecasted market share for ten years to 2025 segmented by seven major markets. In addition, the report includes the hist......
  • Cystitis - Pipeline Insight, 2017
    Published: 05-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, " Cystitis -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Cystitis. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Cystitis. This report provides information on the therapeutic development for Cystitis, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well as discovery products. T......
  • Global Genitourinary Drugs Market Professional Survey Report 2017
    Published: 05-Jul-2017        Price: US 3500 Onwards        Pages: 119
    This report studies Genitourinary Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Pfizer - Eli Lilly - GlaxoSmithKline (GSK) - Bayer - Aste......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs